Gazyva NDA Accepted
- FDA accepted Roche/Genentech's NDA for Gazyva as a treatment for systemic lupus erythematosus (SLE). (x.com) - The filing covers the most common form of lupus via a supplemental Biologics License Application pathway. (x.com) - Acceptance advances the immunology program toward possible approval and will introduce post-market safety and reporting obligations if cleared. (x.com)
Lupus is a disease in which the immune system attacks the body’s own tissues, and Roche’s Genentech unit says the FDA has accepted Gazyva for review in systemic lupus erythematosus, the most common form. (gene.com) The filing is a supplemental Biologics License Application, or sBLA, for Gazyva, also known as obinutuzumab, a medicine already approved in other uses. Genentech announced the acceptance on April 20, 2026. (gene.com) Systemic lupus erythematosus, or SLE, is the form of lupus that affects the whole body rather than one organ, and Roche said it affects more than 3 million people worldwide. The company said better disease control can reduce flares and may help prevent permanent organ damage. (roche.com) Gazyva is an anti-CD20 antibody, which means it is designed to deplete B cells, the immune cells that help drive lupus. Roche said that, if approved in SLE, it would be the first anti-CD20 therapy to directly target B cells for that condition. (roche.com) The FDA acceptance was based on Roche’s Phase III ALLEGORY study, which the company said showed a significant reduction in disease activity versus placebo in people with SLE. The acceptance does not mean the drug is approved; it means the agency will now conduct a formal review of the application. (gene.com) (fda.gov) Gazyva is already moving through lupus in another setting. Genentech said in March 2025 that the FDA accepted a separate sBLA for lupus nephritis, a kidney complication of lupus, based on the Phase III REGENCY trial. (gene.com) That kidney program produced detailed results published in February 2025, when Roche said nearly half of patients on Gazyva plus standard therapy achieved a complete renal response in REGENCY. The SLE filing now extends the company’s immunology push beyond kidney disease to the broader lupus population. (roche.com) (gene.com) Under FDA review policy, biologics supplements such as efficacy sBLAs are assigned either standard or priority review, and the agency’s review can end in approval, a complete response letter, or other action. If Gazyva is cleared for SLE, the approval would add the usual post-market reporting and safety obligations that come with licensed biologics. (fda.gov 1) (fda.gov 2) For patients and doctors, the next step is no longer whether Roche will file in the United States; that happened on April 20. The next question is what the FDA says after it finishes reviewing whether Gazyva’s benefits in SLE outweigh its risks. (gene.com) (fda.gov)
